Medical University of Vienna
- Country
- π¦πΉAustria
- Ownership
- Private
- Established
- 1365-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.meduniwien.ac.at
Clinical Trials
1.2k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (850 trials with phase data)β’ Click on a phase to view related trials
Activity of Mouthwashes Againgst Entamoeba Spp.
- Conditions
- Parasite Infestation
- First Posted Date
- 2025-10-07
- Last Posted Date
- 2025-10-07
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 40
- Registration Number
- NCT07210814
- Locations
- π¦πΉ
Institute for Specific Prophylaxis and Tropical Medicine, Vienna, Austria
Effect of Music on Patient Comfort
- Conditions
- Perioperative Anxiety
- First Posted Date
- 2025-10-03
- Last Posted Date
- 2025-10-03
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 100
- Registration Number
- NCT07206186
- Locations
- π¦πΉ
Medical University of Vienna, Vienna, Vienna, Austria
Impact of Fluid Resuscitation on Venous Congestion in Cardiac Critically-ill Patients
- Conditions
- Cardiac and Aortic SurgeryCardiac AnaesthesiaFluid ResuscitationVenous Congestion
- First Posted Date
- 2025-09-19
- Last Posted Date
- 2025-09-19
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 250
- Registration Number
- NCT07183397
The Choice of Mitral Valve Surgery Type and Mid-term Outcomes in Patients up to 70-years: Results of the AUTHEARTVISIT Study
- Conditions
- Mitral Valve Replacement
- First Posted Date
- 2025-09-11
- Last Posted Date
- 2025-09-18
- Lead Sponsor
- Alissa Florian
- Target Recruit Count
- 3520
- Registration Number
- NCT07168889
Myocardial Perfusion Changes Following Optimal Medical Treatment in Symptomatic Hypertrophic Cardiomyopathy
- Conditions
- Hypertrophic Obstructive Cardiomyopathy \(HOCM\)
- First Posted Date
- 2025-09-02
- Last Posted Date
- 2025-09-02
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 20
- Registration Number
- NCT07150299
- Locations
- π¦πΉ
Medical University of Vienna, Vienna, Austria
- Prev
- 1
- 2
- 3
- 4
- 5
- 213
- Next
News
GLP-1 Drugs Alter Taste Perception, Enhancing Sweetness and Saltiness to Support Appetite Control
About one in five patients taking GLP-1 receptor agonists like Ozempic, Wegovy, and Mounjaro experience enhanced perception of sweetness and saltiness, which correlates with improved appetite control and satiety.
Patritumab Deruxtecan Demonstrates Promising Efficacy in First Prospective Trial for Leptomeningeal Metastases
The HER3-directed antibody-drug conjugate patritumab deruxtecan achieved a 65% three-month overall survival rate in patients with leptomeningeal metastatic disease from solid tumors, meeting the primary endpoint of the TUXEDO-3 trial's cohort 3.
Diabetes Drug Pioglitazone Shows Promising Anti-Tumor Effects in Prostate Cancer
Researchers from the Medical University of Vienna have discovered that PPARπΎ, a protein targeted by type 2 diabetes medications, can influence prostate cancer cell growth.
Respiratory Function Monitoring Improves Supraglottic Airway Device Placement in Neonates, Study Shows
A novel pilot study demonstrates that respiratory function monitoring (RFM) significantly reduces the number of attempts needed for successful supraglottic airway device placement in neonates, including those under 1500g.
Low-Dose Rituximab Shows Transient Efficacy in Autoimmune Hemolytic Anemia
A phase II pilot trial investigated very low doses of rituximab in patients with autoimmune hemolytic anemia (AIHA) to suppress CD20+ cell counts.
MACE Endpoint Faces Scrutiny in Cardiovascular Trials
The major adverse cardiac events (MACE) endpoint, a long-standing standard in cardiovascular trials, is being questioned for its clinical relevance.